Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 0.63 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | SCN5A | Q14524 | 13/20 | 0.51 |
| ▸ | SCN1A | P35498 | 1/20 | 0.51 |
| ▸ | SCN2A | Q99250 | 1/20 | 0.51 |
| ▸ | CYP1A2 | P05177 | 2/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.43 |
| ▸ | HPGD | P15428 | 1/20 | 0.43 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.43 |
| ▸ | HTR6 | P50406 | 1/20 | 0.41 |
| ▸ | CCNC | P24863 | 1/20 | 0.40 |
| ▸ | CDK8 | P49336 | 1/20 | 0.40 |
| ▸ | NPC1 | O15118 | 1/20 | 0.39 |
| ▸ | GAA | P10253 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL936964 | 0.82 | SCN5A (0.65) | SCN5ASCN1ASCN2A | |
| SCHEMBL937017 | 0.81 | SCN5A (0.72) | SCN5ASCN1ASCN2ACYP1A2 | |
| SCHEMBL30498960 | 0.78 | KDM4E (1.00) | KDM4EHSD17B10KMT2ASCN5AALDH1A1 | |
| SCHEMBL937380 | 0.77 | SCN5A (0.56) | SCN5ASCN1ASCN2ACYP1A2 | |
| SCHEMBL6219388 | 0.77 | KDM4E (0.73) | KDM4EHSD17B10KMT2AALDH1A1HPGD | |
| SCHEMBL29565857 | 0.76 | SMN1; SMN2 (0.46) | KMT2ASCN5ASCN1ASCN2AHPGD | |
| SCHEMBL23458576 | 0.73 | KDM4E (0.67) | KDM4EHSD17B10KMT2ACYP1A2ALDH1A1 | |
| SCHEMBL7694480 | 0.72 | SCN5A (0.39) | KDM4EHSD17B10SCN5ASCN1ASCN2A | |
| SCHEMBL19056334 | 0.71 | SCN5A (0.58) | SCN5ASCN1ASCN2A | |
| SCHEMBL937600 | 0.71 | SCN5A (0.57) | SCN5ASCN1ASCN2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | GILEAD PALO ALTO, INC. (US) | 2011-01-27 | — | — | US | claimed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110021521-A1 | FUSED HETEROCYCLIC COMPOUNDS AS ION CHANNEL MODULATORS | KCNJ2, KCNH2, KCNA3 | KDM4E 2541/4885HSD17B10 2866/4885KMT2A 3427/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.